Crispr Therapeutics (NASDAQ:CRSP) had its target price raised by Roth Capital from $65.00 to $100.00 in a research report sent to investors on Tuesday, November 19th, The Fly reports.
Several other analysts have also weighed in on the stock. Goldman Sachs Group lifted their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a research report on Tuesday, November 19th. TheStreet upgraded shares of Crispr Therapeutics from a d rating to a c rating in a research report on Monday, October 28th. Jefferies Financial Group initiated coverage on shares of Crispr Therapeutics in a research report on Thursday, August 1st. They issued a buy rating and a $64.00 price target on the stock. Wells Fargo & Co restated a buy rating on shares of Crispr Therapeutics in a research report on Tuesday, November 19th. Finally, William Blair raised shares of Crispr Therapeutics from a market perform rating to an outperform rating in a research note on Tuesday, November 19th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Crispr Therapeutics presently has an average rating of Buy and an average target price of $69.54.
Shares of CRSP opened at $71.65 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The company has a market capitalization of $3.80 billion, a PE ratio of -20.83 and a beta of 3.15. The company’s fifty day moving average price is $49.98 and its 200 day moving average price is $46.23. Crispr Therapeutics has a one year low of $22.22 and a one year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The company had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In related news, President Rodger Novak sold 33,618 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the sale, the director now directly owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,118 shares of company stock valued at $3,620,760. Corporate insiders own 21.40% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC bought a new position in shares of Crispr Therapeutics in the third quarter valued at about $4,366,000. Orbimed Advisors LLC bought a new position in shares of Crispr Therapeutics in the third quarter valued at about $21,167,000. Granahan Investment Management Inc. MA raised its position in shares of Crispr Therapeutics by 8.3% in the third quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock valued at $1,418,000 after purchasing an additional 2,655 shares during the period. Barclays PLC raised its position in shares of Crispr Therapeutics by 42.7% in the third quarter. Barclays PLC now owns 13,877 shares of the company’s stock valued at $568,000 after purchasing an additional 4,151 shares during the period. Finally, Stifel Financial Corp raised its position in shares of Crispr Therapeutics by 18.0% in the third quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock valued at $400,000 after purchasing an additional 1,491 shares during the period. 49.81% of the stock is currently owned by institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Why is the LIBOR significant?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.